Anik Islam

Anik Islam has a diverse work experience spanning several companies and roles. Anik currently works at CELLINK as the Director - Sales and Applications, overseeing the commercial organization in the Middle East, Africa, Israel, Turkiye, Pakistan, and Nordics regions. Prior to this role, they were a Team Lead at CELLINK, responsible for the MEA & Nordics markets. Anik also served as a Sales Executive at CELLINK, where they managed and developed the Nordic region by connecting and consulting with key opinion leaders in academia, pharma, and industry.

Before joining CELLINK, Anik worked at Merck Group as a Key Account Manager, where they managed academic, pharma, industrial, and diagnostic customers in the Research Markets of Sweden. Anik also held the role of iAccount Manager and Account Manager at Merck Group, contributing to the sales growth within the life science portfolio.

Anik's earlier experience includes working as a Research Engineer at Linköping University, where they specialized in investigating Natural Killer cells and regulatory T cells in Coronary Artery Disease patients. Additionally, they have worked as a Research Fellow at the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology.

Overall, Anik Islam brings a wealth of experience in sales, account management, and research, with a focus on the life sciences industry.

Anik Islam's education history began in 2010 when they enrolled at Linköping University for their Bachelor of Science (BSc) in Medical Biology. Anik completed this degree in 2013. Anik then pursued further studies at Linköping University, where they obtained a Master of Science (MSc) in Experimental and Medical Biosciences from 2013 to 2015. Following this, they attended Fachhochschule Technikum Wien from 2014 to 2015, earning a Master of Science (MSc) in Tissue Engineering and Regenerative Medicine. In 2016, Anik attended the Karolinska Institutet, where they participated in the National Clinical Research School in Chronic Inflammatory Diseases for one year until 2017.